Physician profile
Nirav V Patel
NPI 1871869073
$10,244.10
in general payments reported to CMS, 2019-2025
20 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $165 · 2021: $1,910 · 2022: $663 · 2023: $4,522 · 2024: $1,984 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,180 · Consulting Fee: $2,610 · Travel and Lodging: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.39 |
| Consulting Fee | $2,610.00 |
| Travel and Lodging | $1,349.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,392.66 | 2019-2025 | Camzyos |
| Abbott Laboratories | $2,439.13 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $649.68 | 2022-2025 | Symplicity G3 |
| Abiomed | $207.78 | 2023 | Impella |
| Alnylam Pharmaceuticals INC. | $207.68 | 2023-2025 | Amvuttra, Onpattro |
| Astellas Pharma US INC | $198.99 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $197.66 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $188.54 | 2019-2025 | Wainua |
| Impulse Dynamics (USA) INC. | $183.81 | 2023 | Optimizer |
| Pfizer INC. | $144.12 | 2024-2025 | |
| Akcea Therapeutics, INC. | $122.02 | 2019 | |
| Organogenesis INC. | $72.77 | 2025 | Simplimax, Via Matrix |
| Novartis Pharmaceuticals Corporation | $52.33 | 2019-2024 | |
| Novo Nordisk INC | $38.07 | 2025 | Wegovy |
| Lantheus Medical Imaging, INC. | $32.53 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.60 | 2025 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.33 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $25.27 | 2019 | |
| Bard Peripheral Vascular, INC. | $14.55 | 2021 | |
| Amgen INC. | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.